Maureen Trudeau
About
Maureen Trudeau is a scholar working on Oncology, Cancer Research and Economics and Econometrics.
According to data from OpenAlex, Maureen Trudeau has authored 259 papers receiving a total of 12.8k indexed citations (citations by other indexed papers that have themselves been cited), including 150 papers in Oncology, 113 papers in Cancer Research and 48 papers in Economics and Econometrics. Recurrent topics in Maureen Trudeau's work include Breast Cancer Treatment Studies (107 papers), HER2/EGFR in Cancer Research (53 papers) and Cancer Treatment and Pharmacology (47 papers). Maureen Trudeau is often cited by papers focused on Breast Cancer Treatment Studies (107 papers), HER2/EGFR in Cancer Research (53 papers) and Cancer Treatment and Pharmacology (47 papers). Maureen Trudeau collaborates with scholars based in Canada, United States and United Kingdom. Maureen Trudeau's co-authors include Kathleen I. Pritchard, Wedad Hanna, Steven A. Narod, Rebecca Dent, Ping Sun, Ellen Rawlinson, Carol Sawka, L. Lickley, Pamela J. Goodwin and Marguerite Ennis and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Maureen Trudeau
249 papers receiving 12.5k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Maureen Trudeau Canada | 52 | 7.4k | 5.0k | 3.1k | 2.2k | 1.5k | 259 | 12.8k | ||
| Peter A. Fasching Germany | 55 | 8.0k 1.1× | 6.7k 1.4× | 3.1k 1.0× | 3.0k 1.4× | 1.6k 1.0× | 614 | 14.6k | ||
| Suzette Delaloge France | 56 | 8.4k 1.1× | 5.0k 1.0× | 3.4k 1.1× | 3.8k 1.7× | 1.6k 1.0× | 399 | 13.9k | ||
| Emile E. Voest Netherlands | 70 | 8.5k 1.1× | 4.9k 1.0× | 7.3k 2.4× | 3.1k 1.4× | 1.0k 0.7× | 370 | 18.8k | ||
| Joseph A. Sparano United States | 64 | 10.4k 1.4× | 5.3k 1.1× | 3.7k 1.2× | 2.7k 1.2× | 946 0.6× | 397 | 15.9k | ||
| Jungsil Ro South Korea | 52 | 7.9k 1.1× | 3.6k 0.7× | 3.5k 1.1× | 5.3k 2.4× | 1.4k 0.9× | 189 | 13.3k | ||
| Vera J. Suman United States | 60 | 7.0k 0.9× | 3.6k 0.7× | 3.0k 1.0× | 2.3k 1.0× | 1.5k 0.9× | 273 | 14.8k | ||
| Elsken van der Wall Netherlands | 54 | 4.1k 0.6× | 4.1k 0.8× | 3.9k 1.3× | 1.9k 0.9× | 982 0.6× | 240 | 11.1k | ||
| Angela DeMichele United States | 64 | 7.5k 1.0× | 2.8k 0.6× | 2.6k 0.8× | 4.7k 2.1× | 1.0k 0.7× | 308 | 13.1k | ||
| Dino Amadori Italy | 60 | 6.7k 0.9× | 4.3k 0.9× | 4.5k 1.5× | 3.1k 1.4× | 999 0.6× | 351 | 14.2k | ||
| Rebecca Dent Singapore | 44 | 6.5k 0.9× | 4.1k 0.8× | 3.0k 1.0× | 2.4k 1.1× | 844 0.5× | 186 | 10.2k |
Countries citing papers authored by Maureen Trudeau
Since
Specialization
Citations
This map shows the geographic impact of Maureen Trudeau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maureen Trudeau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maureen Trudeau more than expected).
Fields of papers citing papers by Maureen Trudeau
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Maureen Trudeau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maureen Trudeau. The network helps show where Maureen Trudeau may publish in the future.
Co-authorship network of co-authors of Maureen Trudeau
This figure shows the co-authorship network connecting the top 25 collaborators of Maureen Trudeau. A scholar is included among the top collaborators of Maureen Trudeau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maureen Trudeau. Maureen Trudeau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Moore-Palhares, Daniel, Lakshmanan Sannachi, Adrian Wai Chan, et al.. (2025). Validation of a Quantitative Ultrasound Texture Analysis Model for Early Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer: A Prospective Serial Imaging Study. Cancers. 17(15). 2594–2594.
2.
Freedman, Rachel A., Jennifer L. Caswell‐Jin, Michael J. Hassett, et al.. (2024). Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer—Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update. Journal of Clinical Oncology. 42(18). 2233–2235.
3.
Bielecki, Joanna, Nicholas Mitsakakis, Maureen Trudeau, et al.. (2024). A scoping review to create a framework for the steps in developing condition-specific preference-based instruments de novo or from an existing non-preference-based instrument: use of item response theory or Rasch analysis. Health and Quality of Life Outcomes. 22(1). 38–38.
4.
Dasgupta, Archya, Maureen Trudeau, Sonal Gandhi, et al.. (2024). Apriori prediction of chemotherapy response in locally advanced breast cancer patients using CT imaging and deep learning: transformer versus transfer learning. Frontiers in Oncology. 14. 1359148–1359148.
5.
Trudeau, Maureen, et al.. (2023). The CADTH pCODR Expert Review Committee Process Explained. Comment on Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895. Current Oncology. 30(5). 5047–5049.
6.
Meng, Ying, Raymond M. Reilly, Rossanna C. Pezo, et al.. (2021). MR-guided focused ultrasound enhances delivery of trastuzumab to Her2-positive brain metastases. Science Translational Medicine. 13(615). eabj4011–eabj4011.
7.
Dai, Wei Fang, Craig C. Earle, William K. Evans, et al.. (2021). Building a National Reassessment Process for Oncology Drugs: Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a Simulated Reassessment Exercise. Current Oncology. 28(6). 4645–4654.
8.
Denduluri, Neelima, Mark R. Somerfield, Mariana Chávez‐MacGregor, et al.. (2020). Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update. Journal of Clinical Oncology. 39(6). 685–693.
9.
Sadeghi‐Naini, Ali, Lakshmanan Sannachi, Hadi Tadayyon, et al.. (2017). Chemotherapy-Response Monitoring of Breast Cancer Patients Using Quantitative Ultrasound-Based Intra-Tumour Heterogeneities. Scientific Reports. 7(1). 10352–10352.
10.
Gong, Inna Y., Sunil Verma, Andrew T. Yan, et al.. (2016). Long-term cardiovascular outcomes and overall survival of early-stage breast cancer patients with early discontinuation of trastuzumab: a population-based study. Breast Cancer Research and Treatment. 157(3). 535–544.
11.
Levine, Mark N., Jim A. Julian, Philippe L. Bédard, et al.. (2015). Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario. Journal of Clinical Oncology. 34(10). 1065–1071.
12.
Mittmann, Nicole, Ning Liu, Joan Porter, et al.. (2014). End-of-life home care utilization and costs in patients with advanced colorectal cancer. The Journal of Community and Supportive Oncology. 12(3). 92–98.
13.
Chafe, Roger, Anthony J. Culyer, Mark Dobrow, et al.. (2011). Access to Cancer Drugs in Canada: Looking Beyond Coverage Decisions. Healthcare policy. 6(3). 27–35.
14.
Mittmann, Nicole, et al.. (2010). Cost Effectiveness of tac versus fac in Adjuvant Treatment of Node-Positive Breast Cancer. Current Oncology. 17(1). 7–16.
15.
Nofech‐Mozes, Sharon, Maureen Trudeau, Rebecca Dent, et al.. (2009). Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers. Breast Cancer Research and Treatment. 118(1). 131–137.
16.
Madarnas, Yolanda, Maureen Trudeau, Jacob Franek, et al.. (2008). Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: A systematic review. Cancer Treatment Reviews. 34(6). 539–557.
17.
Kotsopoulos, Joanne, William Zhang, Shiyu Zhang, et al.. (2008). Polymorphisms in folate metabolizing enzymes and transport proteins and the risk of breast cancer. Breast Cancer Research and Treatment. 112(3). 585–593.
18.
Eisen, Andrea, Maureen Trudeau, Wendy Shelley, Hans Messersmith, & Kathleen I. Pritchard. (2008). Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: A systematic review. Cancer Treatment Reviews. 34(2). 157–174.
19.
Goodwin, Pamela J., Marguerite Ennis, Kathleen I. Pritchard, et al.. (2002). Fasting Insulin and Outcome in Early-Stage Breast Cancer: Results of a Prospective Cohort Study. Journal of Clinical Oncology. 20(1). 42–51.
20.
Hanna, Wedad, et al.. (1999). Evaluation of HER-2/neu (erbB-2) status in breast cancer: from bench to bedside.. PubMed. 12(8). 827–34.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Peter A. Fasching Breakdown of academic impact, for papers by Suzette Delaloge Breakdown of academic impact, for papers by Emile E. Voest Breakdown of academic impact, for papers by Joseph A. Sparano Breakdown of academic impact, for papers by Jungsil Ro Breakdown of academic impact, for papers by Vera J. Suman Breakdown of academic impact, for papers by Elsken van der Wall Breakdown of academic impact, for papers by Angela DeMichele Breakdown of academic impact, for papers by Dino Amadori Breakdown of academic impact, for papers by Rebecca Dent